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Abstract
Introduction: This review of literature is to demonstrate a role of group III metabotropic glutamate receptors in main-
taining the level of extracellular glutamate in ischemic stroke and neurodegenerative diseases.
Metabotropic glutamate receptors: mGluRs are classified into three groups. It is suggested that the activation of 
mGluR4 may have a neuroprotective effect.
Role of excitotoxicity in the development and severity of various brain diseases: An increase in the concentration 
of intracellular Ca2+ is the result of excessive accumulation of glutamate in the extracellular space. And a death of nerve 
cells occurs after a sequence of biochemical reactions, which was called excitotoxicity. It is followed by an imbalance 
between glutamatergic excitation and GABA-ergic inhibition. As a result of untimely activation of the inhibitory mech-
anisms, the accumulation of extracellular glutamate, and consequently the death of neurons, continues, which leads to 
more severe manifestations of the cerebral ischemia.
Role of modulation of mGluRs activity in neuroprotection: The literature describes a large number of studies prov-
ing that inhibition of hyperactive glutamatergic transmission has a neuroprotective effect. The most likely mechanisms 
of neuroprotection are inhibition of glutamate production in the substantia nigra, which in turn protects against gluta-
mate-mediated excitotoxicity, and the reduction of the inflammatory effects.
Anti-inflammatory effect of mGluR4 agonists in the mechanism of neuroprotective action: The astroglial com-
ponent may contribute to the protective action of mGluR4 modulators, since astrocytes and microglia have mGluR4.
Conclusion: mGluR4 agonists have the neuroprotective and anti-inflammatory effects.
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Introduction
In neurological diseases, the main mechanism of neuronal 
death is excitotoxicity along with apoptosis, necrosis and 
autophagy (Arkhipov et al. 2013). Excitotoxicity is a com-
mon link in the mechanisms of ischemia and many neuro-
degenerative and inflammatory diseases. Excitotoxicity oc-
curs as a result of hyperactivation of ionotropic glutamate 
receptors, which leads to a disruption of the ion channels 
permeability. The accumulation of intracellular Ca2+ triggers 
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a pathway, which activate a number of enzymes that dama-
ge neurons. The influence on the excitotoxicity mechanisms 
is the main line of a search for neuroprotective agents for 
the treatment of such diseases as epilepsy, ischemic stroke, 
Parkinson’s disease, etc. (Domin et al. 2016). The purpose 
of this article is to demonstrate the role of mGluRs in main-
taining the level of extracellular glutamate in excitotoxicity 
or cerebral ischemia (Moyanova et al. 2011).
Metabotropic glutamate receptors
The main excitatory transmitter of the central nervous sys-
tem is glutamate, which is able to modulate synaptic activi-
ty through ionotropic and metabotropic receptors. Metabot-
ropic receptors can be located on both pre- and postsynaptic 
membranes. Metabotropic glutamate receptors (MGlur) are 
involved in many physiological and pathological proces-
ses, making them a promising target for the development of 
new therapeutic agents (Nicoletti et al. 2011).
Metabotropic receptors transmit a signal through G-pro-
teins, which in turn lead to the opening or closing of the ion 
channels of the cell. MgluRs are classified into 3 groups 
(I-III). Group I mGluRs (mGlu1 and mGlu5) are usually 
located on the postsynaptic membrane and are linked to 
phospholipase C via G-protein, and their activation leads to 
hydrolysis of phosphoinositide and intracellular accumula-
tion of Ca2+. Group II (mGlu2 and mGlu3) and group III 
receptors (mGlu4, mGlu6, mGlu7 and mGlu8) are linked 
to the adenyl cyclase by negative feedback, and their acti-
vation inhibits the producing of cAMP (cyclic adenosine 
monophosphate) (Avdeeva et al. 2018, Johnson et al. 2009).
Group III mGlur receptors are predominantly located 
on the presynaptic terminals of glutamatergic and GA-
BA-ergic neurons, participating in the regulation of synap-
tic transmission (Ferraguti et al. 2008, Selvam et al. 2018). 
The activation of mGlu receptors located on glutamatergic 
neurons causes a decrease in glutamate secretion, thereby 
inhibiting excitatory glutamatergic transmission (Schoepp 
2001). Therefore, it is suggested that the activation of 
these receptors may have a neuroprotective effect.
Role of excitotoxicity in the 
development and severity of 
various brain diseases
In the first hours and minutes after the onset of brain ische-
mia, a focus of necrosis is formed, which is based on the 
reactions of the glutamate-calcium cascade or excitotoxi-
city. The development of the glutamate-calcium cascade 
is triggered by the release of glutamate from the ischemic 
neurons into the intercellular space (Olney 1994).
The initial stage is characterized by a disruption of ion 
transport, resulting in intracellular accumulation of Ca2+, 
which after a sequence of biochemical reactions leads to 
necrotic death of neurons. It is known that the principal 
way of Ca2+ entry into the cell is agonist-activated calci-
um channels, which are controlled by glutamate-activated 
receptors (NMDA receptors) (Hopkins et al. 2009).
The concentration of intracellular Ca2+ and glutamate 
in the extracellular space continues to increase. It is 
known that serum proteins migrate to the brain tissue as a 
result of the Ca2+ accumulation. The presence of albumin 
in conditions of increased glutamate release significantly 
increases the ischemic zone, as it potentiates excitotox-
icity by keeping agonist-activated calcium channels of 
NMDA receptors open for a long time (Linde et al. 1996).
In the final stage, irreversible processes occur (first 
of all, free radical reaction, lipid peroxidation, excessive 
production of nitric oxide, eicosanoids, platelet-activating 
factor, etc.), leading to necrotic cell death (Olney 1994).
T.P.Obrenovitch et al. in their studies showed that the 
maximum concentration of glutamate in the extracellular 
space is reached as early as the first hours of ischemia, 
whereas the concentration of GABA increases only by the 
end of the first day of the pathology development. In the 
normal condition, the mechanisms of glutamate-ergic ex-
citation and GABA-ergic inhibition are in balance, and the 
imbalance between the excitatory and inhibitory systems 
prevents the timely activation of protective inhibitory 
mechanisms of the brain. It is noteworthy that the gluta-
mate level is higher in more severe cerebral ischemia com-
pared to moderately severe ischemia. At the same time, 
GABA concentrations were higher in patients with moder-
ate ischemia than in severe ones (Wahl et al. 1994). These 
data make it possible to suggest that regular administration 
of drugs that potentiate GABA-ergic inhibition, such as 
agonists of group III metabotropic receptors will lead to a 
milder disease progression in the event of a stroke.
Thus, not only excitotoxicity takes part in the develop-
ment of acute cerebral ischemia, but also the imbalance 
between the inhibitory and excitatory mechanisms, shift-
ed towards insufficient inhibition. This is confirmed by 
numerous studies on animals, in which acute cerebral is-
chemia was simulated (Voronkov and Pozdnyakov 2018).
Role of mGluR modulation in 
neuroprotection
The literature describes a large number of studies proving 
that inhibition of hyperactive glutamatergic transmission 
has a neuroprotective effect. With regard to the neuropro-
tective action of antagonists of ionotropic glutamate re-
ceptors (iGluRs) in the central nervous system, the results 
of clinical trials were unsuccessful due to the side effects, 
such as ataxia, sedation, psychotic effects and memory 
impairment (Ikonomidou and Turski 2002), due to which 
they have been widely administered in the clinical prac-
tice. Therefore, modulation of glutamatergic transmission 
may be a more promising neuroprotective strategy than 
direct receptor antagonism (Lea and Faden 2003, Rovira 
et al. 2016).
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Experimental studies have shown the presence of the 
neuroprotective effect of group III mGluRs agonists. Neu-
roprotective efficacy of drugs affecting mGluR4 was also 
assumed in treating Parkinson’s disease, autism and cer-
ebellar ataxia (Power and Empson 2014). In haloperidol 
and reserpine models of parkinsonism the administration 
of mGluR4 agonists resulted in a decrease in the symptoms 
and signs (Niswender and Conn 2010). This study also 
showed that the activation of mGluR4 may ultimately pre-
vent continuing neurodegeneration in Parkinson’s disease.
MGluR4 receptor-mediated neuroprotection may be 
based on various mechanisms. The two most likely mecha-
nisms are: inhibition of glutamate production in the substan-
tia nigra, which in turn protects against glutamate-mediated 
excitotoxicity, and the reduction of the inflammatory effects.
As for the hypothesis of inhibition of glutamate pro-
duction, previously conducted in vitro studies showed that 
L-AP4, the agonist of group III metabotropic glutamate 
receptors, suppressed the glutamate-mediated excitation 
of dopaminergic neurons in the substantia nigra pars com-
pacta, and the local intranigral administration of L-SOP re-
duced the release of glutamate in the substantia nigra pars 
compacta (Mercier and Lodge 2014). As a result, it was 
concluded that mGluR4 are a key subtype of metabotropic 
receptors responsible for inhibition of glutamatergic excita-
tion in the substantia nigra (Valenti et al. 2005). In further 
studies, a putative neuroprotective effect of mGluR4 ago-
nists, including inhibition of glutamate release in the sub-
stantia nigra, was studied. The administration of another 
positive allosteric modulator PHCCC ((7E)-7-hydroxyimi-
no-N-phenyl-1,7 a-dihydrocyclopropa[b]chromene-1a-car-
boxamide) in the globus pallidus leads to the elimination of 
the MPTP-induced motor disorders. Thus, the neuropro-
tection in the MPTP-induced parkinsonism model is based 
on the mGluR4-mediated normalization of glutamatergic 
excitation in the substantia nigra or indirectly through the 
correction of the pallid subthalamic pathway and the subse-
quent inhibition of glutamatergic excitation in the substan-
tia nigra pars compacta (Battaglia et al. 2006).
In most studies, group III mGluRs agonists were adminis-
tered mainly before, simultaneously, or shortly after the dis-
ease onset. The study of neuroprotective effect of group III 
mGluRs agonist ACPT-I after its delayed administration (30 
min-3 hours) showed its effect on kainite-induced excitotox-
icity. The main conclusion of this study was that ACPT-I re-
duced kainite-induced neuronal damage in vitro and in vivo.
Anti-inflammatory effect of 
mGlur4 agonists neuroprotection
It is known that activated microglia participates in neuro-
degeneration of dopaminergic neurons in the substantia 
nigra by the release of pro-inflammatory cytokines and re-
active oxygen species. Normally, neurons with astrocytes 
release factors that inhibit the microglia activity. A brain 
injury leads to the microglia activation and its attachment 
to neurons. Further, a cytoskeleton of the microglia cells 
is disrupted, and microglia acquires phagocytic activity. 
The activated microglia releases inflammatory cytoki-
nes, which increase the inflammatory response, as well as 
neurotoxins (TNF-α and others), which leads to damage 
of other neurons. Experimental animal models showed 
the importance of inflammatory processes associated with 
activation of microglia in the degeneration of nigrostriatal 
dopaminergic neurons (Kucheryanu et al. 2012).
The presence of mGluR4 on astrocytes and microglia 
increases the likelihood of the astroglial component con-
tributing to the protective action of mGluR4 modulators 
(Taylor et al. 2003).
Inflammation plays a key role in the pathogenesis of many 
neurologic diseases, including Parkinson’s disease (Schap-
ira 2009, Tansey and Goldberg 2010). In 6-OHDA-induced 
parkinsonian syndrome in rats, microglia is activated, and 
the level of pro-inflammatory cytokines in the corpus stri-
atum and substantia nigra pars compacta increases, after 
which the microglial cells group along the dopaminergic 
neurons and become phagocytic (Cicchetti et al. 2002). 
In experiments on mice, L-AP4 administration decreased 
pro-inflammatory cytokines production, which proves the 
role of mGluR4, including astroglial ones in the potential 
anti-inflammatory action (Besong et al. 2002). In another 
study, the administration of a positive allosteric modulator 
of mGluR4 – VU0155041 (cis-2-[[(3,5-Dichlorophenyl)
amino]carbonyl] cyclohexanecarboxylic acid) signifi-
cantly decreased the level of GFAP (glial fibrillary acidic 
protein – a predictor of the neuron cell death) and IBA-1 
(ionized calcium-binding adaptor molecule 1) in mice with 
6-OHDA-induced astroglial neurotoxicity, which also con-
firms this theory. Although these mechanisms have been 
just started to be studied, the obtained results support the 
assumption about the anti-inflammatory effect of mGluR4.
Conclusion
Metabotropic glutamate receptors are involved in the ac-
tivation of intracellular metabolism and play an important 
role in the regulation of the Ca2+ entry into the cell caused 
by the activation of NMDA receptors in cerebral ischemic 
stroke, Parkinson’s disease and inflammation.
MGluR4 agonists correct the imbalance between GA-
BA-ergic inhibition and glutamate-ergic excitation, pro-
viding neuroprotective and anti-inflammatory effects. In 
this regard, drugs modulating mGluR4 are involved in the 
activation of intracellular metabolism and can be recom-
mended for use in the treatment of Parkinson’s disease, 
acute cerebral ischemia and inflammatory diseases (Bossi 
et al. 2018, Lester et al. 2010).
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